Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 469-475

  Yachi, Kazunari ^a   Watanabe, Takao ^a   Ohta, Takashi ^a   Fukushima, Takao ^a   Yoshino, Atsuo ^a   Ogino, Akiyoshi ^a   Katayama, Yoichi ^a   Nagase, Hiroki ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glioblastoma; Methylation specific PCR; MGMT; Promoter methylation; Sequencing analysis

Indexed keywords

BIOLOGICAL MARKER; BISULFITE; CARBOPLATIN; ETOPOSIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; PROCARBAZINE; VINCRISTINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; ASSAY; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; DRUG SENSITIVITY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REPRODUCIBILITY; WESTERN BLOTTING; BRAIN TUMOR; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; VALIDATION STUDY;

ADULT; AGED; BASE SEQUENCE; BLOTTING, WESTERN; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); REPRODUCIBILITY OF RESULTS; SUPRATENTORIAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 54849188000     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000029     Document Type: Article

References (31)

1. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.
2. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399, 2002.
4. Kaina B and Christmann M: DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40: 354-367, 2002.
5. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999.
6. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
7. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
8. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113: 581-587, 2005.
9. Cankovic M, Mikkelsen T, Rosenblum ML and Zarbo RJ: A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87: 392-397, 2007.
10. Grasbon-Frodl EM, Kreth FW, Ruiter M, et al: Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121: 2458-2464, 2007.
11. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
12. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11: 5167-5174, 2005.
13. Jeuken JWM, Cornelissen SJB, Vriezen M, et al: MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87: 1055-1065, 2007.
14. Mikeska T, Bock C, El-Maarri O, et al: Optimization of quantitative MGMT promoter methylation analysis using pyro-sequencing and combined bisulite restriction analysis. J Mol Diagn 9: 368-381, 2007.
15. Kleihues P, Burger PC, Collins VP, Newcomb EW, Obgaki H and Cavenee WK: Glioblastoma. In: WHO Classification of Tumors: Pathology and Genetics. Tumors of the Nervous System. Kleihues P and Cavenee WK (eds). International Agency for Research on Cancer, Lyon, pp29-39, 2000.
16. 6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis. Neurol Med Chir (Tokyo) 46: 387-393, 2006.
17. INK4a genes in oligodendrogliomas. Acta Neuropathol 101: 185-189, 2001.
18. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P and Ohgaki H: Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60: 1181-1189, 2001.
19. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13: 176-184, 2003.
20. Capper D, Mittelbronn M, Meyermann R and Schittenhelm J: Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 115: 249-259, 2008.
21. Möllemann M, Wolter M, Felsberg J, Collins VP and Reifenberger G: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113: 379-385, 2005.
22. 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87: 71-78, 2008.
23. 6-methylguanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis (2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9: 1461-1468, 2003.
24. Crinière E, Kaloshi G, Laigle-Donadey F, et al: MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83: 173-179, 2007.
25. 6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5: 2531-2539, 2006.
26. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al: MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 16: 59-65, 2008.
27. 6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25: 1470-1475, 2007.
28. 6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 70: 333-340, 2004.
29. 6-methylguanine-DNA methyltransferase and the mismatch repair system. Int J Oncol 29: 785-797, 2006.
30. 6-methylguanine-DNA methyltransferase. Carcinogenesis 24: 625-635, 2003.
31. 6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 67: 580-584, 2007.